{"title":"N末端原C型利钠肽和内皮素-1水平与动脉高血压患者在COVID-19治疗6个月后出现心血管并发症风险的关系","authors":"Shuvalova A.S. Shuvalova, Prokofieva T.V. Prokofieva, Polunina O.S. Polunina, Polunina E.A. Polunina","doi":"10.18565/pharmateca.2024.1.85-90","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":20153,"journal":{"name":"Pharmateca","volume":" 6","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Association of N-terminal pro C-type natriuretic peptide and endothelin-1 levels with the risk of cardiovascular complications in arterial hypertension six months after COVID-19\",\"authors\":\"Shuvalova A.S. Shuvalova, Prokofieva T.V. Prokofieva, Polunina O.S. Polunina, Polunina E.A. Polunina\",\"doi\":\"10.18565/pharmateca.2024.1.85-90\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":20153,\"journal\":{\"name\":\"Pharmateca\",\"volume\":\" 6\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmateca\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18565/pharmateca.2024.1.85-90\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmateca","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18565/pharmateca.2024.1.85-90","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Association of N-terminal pro C-type natriuretic peptide and endothelin-1 levels with the risk of cardiovascular complications in arterial hypertension six months after COVID-19